🔗 Permalink

Inventor profile of:

Peter Sandner

City:

Wuppertal

Country:

Germany

Published Applications:

36

Last publication date:

2025-01-23

Top Assignees for applications by Peter Sandner

The entities that hold a legal rights for patent applications filed by inventor Sandner Peter:

Bayer Pharma Aktiengesellschaft 9 Berlin, Germany
BAYER HEALTHCARE AG 6 Leverkusen, Germany
Bayer Aktiengesellschaft 5 Leverkusen, Germany
Bayer Intellectual Property GmbH 4 Monheim, Germany
Bayer Schering Pharma Aktiengesellschaft 3 Berlin, Germany
ADVERIO PHARMA GMBH 2 SCHONEFELD, Germany
BAYER PHARAMA AKTIENGESELLSCHAFT 1 Berlin, Germany
BAYER PHARMA AKTIENGESELL SCHAFT 1 Berlin, OT, Germany
Adverio Pharma GmbH 1 Leverkusen, Germany
Bater Healthcare AG 1 Leverkusen, Germany

Recent patent applications by Sandner Peter

Peter Sandner from Wuppertal, DE has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-01-23

US20250026737A1

Chemistry; metallurgy

SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS

#2 | 2024-04-04

US20240109864A1

Chemistry; metallurgy

SUBSTITUTED PYRAZOLYL PIPERIDINE CARBOXYLIC ACIDS

#3 | 2024-03-28

US20240101528A1

Chemistry; metallurgy

SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS

#4 | 2024-02-15

US20240051935A1

Chemistry; metallurgy

SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS

#5 | 2023-11-02

US20230346777A1

Human necessities

USE OF SGC ACTIVATORS FOR THE TREATMENT OF OPHTHALMOLOGIC DISEASES

#6 | 2023-08-24

US20230265072A1

Chemistry; metallurgy

Substituted pyrazolo piperidine carboxylic acids

#7 | 2023-06-29

US20230201174A1

Human necessities

COMBINATION OF FINERENONE AND A SGLT2 INHIBITOR FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR AND/OR RENAL DISEASES

#8 | 2022-09-01

US20220274958A1

Chemistry; metallurgy

SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS

#9 | 2022-08-04

US20220241273A1

Human necessities

USE OF SGC ACTIVATORS FOR THE TREATMENT OF OPHTHALMOLOGIC DISEASES

#10 | 2022-08-04

US20220241255A1

Human necessities

COMBINATION CONTAINING SGC ACTIVATORS AND MINERALOCORTICOID RECEPTOR ANTAGONISTS

#11 | 2022-04-28

US20220128561A1

METHODS TO DETERMINE WHETHER A SUBJECT IS SUITABLE OF BEING TREATED WITH AN AGONIST OF SOLUBLE GYANYLYL CYCLASE (SGC)

#12 | 2021-04-29

US20210121461A1

Human necessities

Combination containing sGC stimulators and mineralocorticoid receptor antagonists

#13 | 2021-04-29

US20210121447A1

Human necessities

Use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases

#14 | 2021-02-25

US20210052528A1

Human necessities

THE USE OF SGC ACTIVATORS AND SGC STIMULATORS FOR THE TREATMENT OF COGNITIVE IMPAIRMENT

#15 | 2019-12-05

US20190371469A1

Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group

#16 | 2019-08-29

US20190262340A1

Human necessities

Combination containing SGC stimulators and mineralocorticoid receptor antagonists

#17 | 2019-07-25

US20190224176A1

Human necessities

Combination containing sGC activators and mineralocorticoid receptor antagonists

#18 | 2018-06-21

US20180169095A1

Human necessities

THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC)

#19 | 2016-06-09

US20160158233A1

Human necessities

SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis

#20 | 2015-10-29

US20150306084A1

Human necessities

ADENOSINE A1 AGONISTS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION

#21 | 2014-09-25

US20140288079A1

Human necessities

SGC STIMULATORS OF SGC ACTIVATORS IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION

#22 | 2014-02-06

US20140038956A1

Chemistry; metallurgy

Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)

#23 | 2013-08-15

US20130210797A1

Chemistry; metallurgy

Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension

#24 | 2013-02-07

US20130035340A1

Human necessities

sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS

#25 | 2012-03-08

US20120058983A1

Human necessities

Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension

#26 | 2012-01-26

US20120022028A1

Human necessities

SGC STIMULATORS OR SGC ACTIVATORS IN COMBINATION WITH PDE5 INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION

#27 | 2011-04-21

US20110092500A1

Human necessities

SGC STIMULATORS, SGC ACTIVATORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF HEARING IMPAIRMENT

#28 | 2010-08-19

US20100210643A1

Human necessities

sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS

#29 | 2010-07-22

US20100184769A1

Chemistry; metallurgy

PDE INHIBITORS FOR THE TREATMENT OF HEARING IMPAIRMENT

#30 | 2010-05-06

US20100113452A1

Human necessities

Compounds for treating pulmonary hypertension

#31 | 2010-02-11

US20100035888A1

Human necessities

Diaryl Urea for Treating Pulmonary Hypertension

#32 | 2010-01-14

US20100010024A1

Chemistry; metallurgy

USE OF1,4-DIARYL-DIHYDROPYRIMIDINE-2-ON DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTENSION

#33 | 2009-07-23

US20090186896A1

Chemistry; metallurgy

PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders

#34 | 2009-07-09

US20090176791A1

Human necessities

Diaryl Ureas for Treating Pulmonary Hypertension

#35 | 2008-09-04

US20080214654A1

Chemistry; metallurgy

Substituted Benzyloxy-Phenylmethylamide Derivatives

#36 | 2005-10-06

US20050222247A1

Chemistry; metallurgy

Chroman derivatives

InventorID:

80001 ⎘